CLISEQ

Company Overview

Snapshot

Founded in January 2025, CLISEQ operates with 1–10 employees, focusing on advancing minimally invasive diagnostic approaches for hematologic disorders. In September 2025, the company announced a collaboration with 10x Genomics and the Weizmann Institute to investigate single-cell applications in hematology clinical diagnostics.

Business overview

CLISEQ is a translational diagnostics company specializing in hematology diagnostics. Spun out of the Weizmann Institute of Science, the company develops minimally invasive diagnostic approaches for hematologic disorders, leveraging a patented technology for peripheral blood single-cell RNA sequencing (scRNA-seq). This technology aims to detect conditions like myelodysplastic syndromes (MDS) as an alternative to bone-marrow aspiration. CLISEQ operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Test Diagnostics & Screening, serving the healthcare and life sciences markets.

Strategic signal

In September 2025, CLISEQ announced a significant collaboration with 10x Genomics and the Weizmann Institute to explore single-cell applications in hematology clinical diagnostics. This partnership is crucial for validating CLISEQ's patented scRNA-seq technology through an international multi-site clinical trial (PERIBLOOD) involving over 1,500 participants. This signals strong industry validation and a clear path towards commercialization and integration into future hematology diagnostics workflows.

Company Intelligence Q&A

What is CLISEQ's core technology?

CLISEQ utilizes a patented technology developed at the Weizmann Institute of Science that enables the use of peripheral blood single-cell RNA sequencing (scRNA-seq) for minimally invasive diagnostic approaches in hematologic disorders.

What is the primary application of CLISEQ's technology?

The technology is primarily used to detect conditions such as myelodysplastic syndromes (MDS) as an alternative to traditional bone-marrow aspiration.

Which organizations is CLISEQ collaborating with on clinical trials?

CLISEQ is conducting an international multi-site clinical trial (PERIBLOOD) in partnership with 10x Genomics, Inc. and the Weizmann Institute.

What is the scope of the PERIBLOOD clinical trial?

The PERIBLOOD clinical trial is an international multi-site study enrolling over 1,500 participants across several continents to validate the clinical utility of CLISEQ's technology.

When was CLISEQ founded?

CLISEQ was founded in January 2025.